标题
New therapeutic agents for acromegaly
作者
关键词
-
出版物
Nature Reviews Endocrinology
Volume 12, Issue 2, Pages 90-98
出版商
Springer Nature
发表日期
2015-11-27
DOI
10.1038/nrendo.2015.196
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Treatment of acromegaly in the era of personalized and predictive medicine
- (2015) Manuel Puig Domingo CLINICAL ENDOCRINOLOGY
- A Structural and Functional Acromegaly Classification
- (2015) Daniel Cuevas-Ramos et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Safety and Efficacy of Oral Octreotide in Acromegaly: Results of a Multicenter Phase III Trial
- (2015) Shlomo Melmed et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Long-Term Efficacy and Safety of Pegvisomant in Combination With Long-Acting Somatostatin Analogs in Acromegaly
- (2014) S. J. C. M. M. Neggers et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Acromegaly Clinical Trial Methodology Impact on Reported Biochemical Efficacy Rates of Somatostatin Receptor Ligand Treatments: A Meta-Analysis
- (2014) John D. Carmichael et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Acromegaly: An Endocrine Society Clinical Practice Guideline
- (2014) Laurence Katznelson et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Pasireotide Versus Octreotide in Acromegaly: A Head-to-Head Superiority Study
- (2014) A. Colao et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Successful Mortality Reduction and Control of Comorbidities in Patients With Acromegaly Followed at a Highly Specialized Multidisciplinary Clinic
- (2014) Moises Mercado et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Pharmacological treatment of acromegaly: its place in the overall therapeutic approach
- (2014) Evgenia Korytnaya et al. JOURNAL OF NEURO-ONCOLOGY
- Mortality in acromegaly reduced with multimodal therapy
- (2014) Nienke R. Biermasz Nature Reviews Endocrinology
- Expert consensus document: A consensus on the medical treatment of acromegaly
- (2014) Andrea Giustina et al. Nature Reviews Endocrinology
- A Novel Suspension Formulation Enhances Intestinal Absorption of Macromolecules Via Transient and Reversible Transport Mechanisms
- (2014) Shmuel Tuvia et al. PHARMACEUTICAL RESEARCH
- The role of pasireotide in the treatment of acromegaly
- (2014) Nicholas A Tritos Lancet Diabetes & Endocrinology
- Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial
- (2014) Mônica R Gadelha et al. Lancet Diabetes & Endocrinology
- Emerging drugs for acromegaly
- (2013) Sylvère Störmann et al. EXPERT OPINION ON EMERGING DRUGS
- Octreotide for acromegaly treatment: a reappraisal
- (2013) Andrea Giustina et al. EXPERT OPINION ON PHARMACOTHERAPY
- Hyperglycemia Associated With Pasireotide: Results From a Mechanistic Study in Healthy Volunteers
- (2013) Robert R. Henry et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Tumor Shrinkage With Lanreotide Autogel 120 mg as Primary Therapy in Acromegaly: Results of a Prospective Multicenter Clinical Trial
- (2013) Philippe J. Caron et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- A Paradigm Shift in the Monitoring of Patients With Acromegaly: Last Available Growth Hormone May Overestimate Risk
- (2013) Mark Sherlock et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Lanreotide extended-release aqueous-gel formulation, injected by patient, partner or healthcare provider in patients with acromegaly in the United States: 1-year data from the SODA registry
- (2013) Roberto Salvatori et al. Pituitary
- Oral Octreotide Absorption in Human Subjects: Comparable Pharmacokinetics to Parenteral Octreotide and Effective Growth Hormone Suppression
- (2012) S. Tuvia et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Long-Term Safety of Pegvisomant in Patients with Acromegaly: Comprehensive Review of 1288 Subjects in ACROSTUDY
- (2012) A. J. van der Lely et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Comparative effectiveness review of treatment options for pituitary microadenomas in acromegaly
- (2012) Nicholas F. Marko et al. JOURNAL OF NEUROSURGERY
- The changing face of acromegaly—advances in diagnosis and treatment
- (2012) Antônio Ribeiro-Oliveira Jr et al. Nature Reviews Endocrinology
- Growth hormone granulation pattern and somatostatin receptor subtype 2A correlate with postoperative somatostatin receptor ligand response in acromegaly: a large single center experience
- (2012) Jessica Brzana et al. Pituitary
- Meta-Analysis on the Effects of Octreotide on Tumor Mass in Acromegaly
- (2012) Andrea Giustina et al. PLoS One
- Sustained-Release Delivery of Octreotide from Biodegradable Polymeric Microspheres
- (2011) Yun-Seok Rhee et al. AAPS PHARMSCITECH
- DG3173 (somatoprim), a unique somatostatin receptor subtypes 2-, 4- and 5-selective analogue, effectively reduces GH secretion in human GH-secreting pituitary adenomas even in Octreotide non-responsive tumours
- (2011) U Plöckinger et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Impenetrable barriers or entry portals? The role of cell–cell adhesion during infection
- (2011) Matteo Bonazzi et al. JOURNAL OF CELL BIOLOGY
- Endoscopic Transsphenoidal Surgery for Acromegaly: Remission Using Modern Criteria, Complications, and Predictors of Outcome
- (2011) John A. Jane et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Medical therapy in acromegaly
- (2011) Mark Sherlock et al. Nature Reviews Endocrinology
- Clinical, quality of life, and economic value of acromegaly disease control
- (2011) A. Ben-Shlomo et al. Pituitary
- Mortality in Patients with Pituitary Disease
- (2010) Mark Sherlock et al. ENDOCRINE REVIEWS
- Magnetic Resonance Imaging as a Predictor of Response to Somatostatin Analogs in Acromegaly after Surgical Failure
- (2010) Manel Puig-Domingo et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Clinical efficacy and safety results for dose escalation of somatostatin receptor ligands in patients with acromegaly: a literature review
- (2010) Maria Fleseriu Pituitary
- A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long-acting octreotide in patients with acromegaly
- (2009) Peter J. Trainer et al. CLINICAL ENDOCRINOLOGY
- Pituitary-independent effect of octreotide on IGF1 generation
- (2009) Ana Pokrajac et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Acromegaly pathogenesis and treatment
- (2009) Shlomo Melmed JOURNAL OF CLINICAL INVESTIGATION
- A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly
- (2008) I M Holdaway et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Quantitative analysis of somatostatin receptor subtypes (1–5) gene expression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAR
- (2008) Giselle F Taboada et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- A Critical Analysis of Clinically Available Somatostatin Analog Formulations for Therapy of Acromegaly
- (2008) Robert D. Murray et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Lipodystrophy in Patients with Acromegaly Receiving Pegvisomant
- (2008) Vivien S. Bonert et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Differential Effects of Octreotide and Pasireotide on Somatostatin Receptor Internalization and Traffickingin Vitro
- (2008) Sarah Lesche et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Acromegaly
- (2008) Philippe Chanson et al. Orphanet Journal of Rare Diseases
- Growth hormone-releasing hormone as an agonist of the ghrelin receptor GHS-R1a
- (2008) F. F. Casanueva et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now